Celgene Corporation (NASDAQ:CELG) expanded its 11 month-old partnership with the privately held Forma Therapeutics. The expanded deal gives Celgene the exclusive option to acquire Forma under certain circumstances. The news of the second deal between the two companies impacted Celgene’s stock positively. Celgene Corporation (NASDAQ:CELG) stock opened today at $140.01 and is currently trading at $143.24. The stock showed a negative weekly performance of -5.72%.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) executives met again with FDA officials in March to nail down a regulatory path for the Duchenne muscular dystrophy drug eteplirsen. The company has promised to update investors about the outcome of the FDA meeting, but without saying exactly when. This week, Sarepta cancelled a presentation at an investor conference, which of course, has everyone speculating about an imminent eteplirsen announcement. Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock opened at $25.25, in current trading session and currently is at $25.90, by gaining 4.48%. The 52 week range of $12.12 – $55.61. Company’s market capitalization is 978.38 million.
VIVUS, Inc. (NASDAQ:VVUS) yesterday announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014. VIVUS, Inc. (NASDAQ:VVUS) stock is currently trading at $4.96. The EPS of the stock is -1.73. Company’s market capitalization is 511.68 million.
Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, on 2 April announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company’s Asia Pacific and Africa (APACA) region. Actavis plc (NYSE:ACT) stock opened the session at $195.01, and now is at $196.48. The 52 week range of the Actavis plc (NYSE:ACT) stock remained $96.01 – $230.77 and the day range was $194.02 – $198.45.